28-day Repeat Dose Study of GSK573719

Inclusion Criteria: * A signed and dated written informed consent prior to study participation * Males or females of non-childbearing potential * 40 to 80 years of age * COPD diagnosis * 10 pack-years history or greater of cigarette smoking * Post-bronchodilator FEV1/FVC ratio of 0.70 or less * Post-bronchodilator FEV1 of 25 to 70% of predicted normal Exclusion Criteria: * Asthma * Other significant respiratory disorders besides COPD, including alpha-1 deficiency * Previous lung resection surgery * Chest X-ray or CP scan showing clinically significant abnormalities not due to COPD * Use of oral steroids or antibiotics for a COPD exacerbation within 6 weeks of screening * Hospitalization for COPD or pneumonia within 3 months of screening * Any significant disease that would put subject at risk through study participation * BMI greater than 35 * Pacemaker * Significantly abnormal ECG or clinical lab finding (including Hepatitis B or C) * Cancer * Allergy or hypersensitivity to anticholinergics or inhaler excipients * Diseases that would contraindicate the use of anticholinergics * Use of oral corticosteroids within 6 weeks of screening * Use of long-acting beta-agonists within 48 hours of screening * Use of tiotropium within 14 days of screening * Use of theophyllines or anti-leukotrienes within 48 hours of screening * Use of short-acting bronchodilators within 4 to 6 hours of screening * Use of investigational medicines within 30 days of screening * Use of high dose inhaled corticosteroids * Use of long-term oxygen therapy, CPAP or NIPPV * Participation in acute phase of pulmonary rehabilitation program * History of alcohol or drug abuse within 2 years prior to screening * History of psychiatric disease limiting validity of consent * Affiliation with the investigative site * Previous use of GSK573719